BATON ROUGE, LA--(NewMediaWire - Jul 18, 2017) - Dewmar
International BMC, Inc. (OTC PINK: DEWM) announced
today that it has filed a provisional patent with the United States
Patent and Trademark Office for the treatment of lung cancer with
cannabinoids. The title of the provisional patent filing
is Cannabinoid Formulation to Treat Lung Cancer.
The invention relates to an inhalation pharmaceutical
formulation of metered and/or titrated doses of certain types of
cannabinoids to treat lung cancer using either a pressurized
inhaler or a dry powder inhaler. The invention also pertains to the
pharmaceutically acceptable derivatives of the compounds of the
invention, to processes for the preparation of these compounds, to
chemical intermediates useful in preparation of these compounds, to
a method of combating cancerous tumors in a mammal, and to
pharmaceutical compositions containing these compounds or their
derivatives.
Dr. Marco Moran, CEO of Dewmar International, is the former
Director of Pharmacy and head of U.S. Regulatory Affairs
for INO Therapeutics ("INO") once located in Port Allen,
LA but is now a part of Mallinckrodt Pharmaceuticals via
a $2.3 billion acquisition of Ikaria. INO provides
Inhaled Nitric Oxide, for treating hypoxic respiratory failure in
newborns. INO was a private firm that patented, manufactured and
shipped the first FDA approved gaseous drug in the United States to
help premature babies to quickly develop their lung capacity. Dr.
Moran played an integral role in the early 2000s in working with
the company's France headquarters to spread these life-saving
inhalation therapies across many neonatal intensive care units
(ICUs) across the United States.
"I traveled from state to state with our quality assurance team
to assure the proper set up and implementation of our innovative
inhalation systems," said Dr. Moran. "I learned many
state-of-the-art inhalation dosing forms and techniques from this
forward-thinking company who was in the process of trying to create
an 'inhalation Viagra' that could work in a matter of seconds as
opposed to minutes. INO is the entity that helped expand my
creativity when it came to new product development and
implementation; they encouraged me to think outside of the box.
This invaluable experience with INO has perfectly positioned me to
maximize my talents to take Dewmar to greater heights than I could
have ever imagined."
By combining proven science with innovative methods which allow
cancer fighting cannabinoid compounds to be delivered to the site
of the cancerous tissue in a metered, precise therapeutic dose, Dr.
Moran believes this invention will offer significant advantages
over some of the conventional chemotherapies that have been used in
the treatment of lung cancer. Dewmar International has already
recruited a team of research physicians, including oncology
specialists, to test this invention in the near future. They
continue to recruit both oncologists and respiratory
therapists.
"Our premise is simple; we asked this basic question: 'How many
routine or chronic marijuana smokers do you know that have ever
been diagnosed with lung cancer?' No one could really come back
with a single patient of record," stated Dr.
Moran. "Cannabinoids have the potential to be one of the most
effective treatments of lung cancer ever introduced to oncologists.
We have taken this medical hypothesis one step further to deliver
these chemicals in a metered, controlled dose which is what medical
doctors are seeking."
As previously announced, Dewmar's medical cannabis intellectual
property assets will be held by its second-tier subsidiary,
Cannabis Intellectual Property Holdings, LLC. The Company believes
the development of its cannabis delivery mechanisms designed for
specific disease states will bring a new era in targeted
therapeutics to improve patient care and outcomes.
About Dewmar International BMC, Inc.
Dewmar International BMC, Inc. is a certified service-disabled
veteran-owned business concern, new product development,
manufacturing and brand management company. Established in 2003,
Dewmar's primary business strategy has been in creating high profit
margins with functional foods and beverages, such as Lean Slow
Motion Potion™ and Kush Cakes which is rated as one
of the top national selling relaxation beverages and brownie in the
U.S. market. The company has offices in Clinton, MS; Houston, TX:
Denver, CO and New Orleans, LA.
Follow Dewmar on its
official Facebook and Twitter sites where the
CEO is inclined to provide information, sometimes on a daily basis,
about some of the Company's current activities and key staff
activities. Also, subscribe to our Company Newsletter on
the bottom right of our homepage on our website to
receive updates as well.
Click here for the Safe Harbor Statement. Investment
& Company
